These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 210446)

  • 1. Randomized double blind study of 1, 25(OH)2D3 in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC; Kleit SA
    Proc Clin Dial Transplant Forum; 1977; 7():166-9. PubMed ID: 210446
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcitriol in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
    Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
    Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
    Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
    Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
    Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
    Teitelbaum SL
    Ann Intern Med; 1981 Mar; 94(3):404-5. PubMed ID: 6894359
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure.
    Delling G; Lühmann H; Bulla M; Fuchs C; Henning HV; Jansen JL; Kohnle W; Schulz W
    Contrib Nephrol; 1980; 18():105-21. PubMed ID: 7353369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical use of synthetic 1,25-dihydroxycholecalciferol.
    Evans IM; Boulton-Jones M; Doyle FH; Joplin GF; Lockwood M; Matthews EW; MacIntyre I
    Calcif Tissue Res; 1976 Aug; 21 Suppl():236-41. PubMed ID: 782663
    [No Abstract]   [Full Text] [Related]  

  • 14. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
    Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I
    Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,25-dihydroxycholesterol treatment of long-term haemodialysed patients with renal osteodystrophy.
    Váry L
    Int Urol Nephrol; 1980; 12(3):241-7. PubMed ID: 7251289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)].
    Bulla M; Delling G; Benz-Bohm G; Stock GJ; Sánchez de Reutter A; Ziegler R; Lühmann H; Severin M; Kalbitzer E; Manegold C
    Klin Wochenschr; 1980 May; 58(10):511-9. PubMed ID: 7392529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: Some long-term effects of 1,25 dihydroxycholecalciferol (1,25(OH)2D3) in man.
    Henderson RG; Ledingham JG; Oliver DO; Small DG; Russell RG; Smith R; Walton RJ; Norman AW
    Clin Sci Mol Med; 1974 Feb; 46(2):10P. PubMed ID: 4817248
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.
    Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A
    Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
    Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.